Epigenetic Signatures of Asthma: A Comprehensive Study of DNA Methylation and Clinical Markers - Van Asselt, Austin J.; Beck, Jeffrey J.; Johnson, Brandon N.; Finnicum, Casey T.; Kallsen, Noah; Viet, Sarah; Huizenga, Patricia; Ligthart, Lannie; Hottenga, Jouke-Jan; Pool, René; Maitland-van der Zee, A.H; Vijverberg, S.J.; et al. (medRxiv, 2024)
Background Asthma, a complex respiratory disease, presents with inflammatory symptoms in the lungs, blood, and other tissues. We investigated the relationship between DNA methylation and 35 clinical markers of asthma. The Illumina Infinium EPIC v1 methylation array was used to evaluate 742,442 CpGs in whole blood samples from 319 participants. They were part of the Netherlands Twin Register from families with at least one member suffering from severe asthma. Repeat blood samples were taken after 10 years from 182 of these individuals. Principal component analysis (PCA) on the clinical markers yielded ten principal components (PCs) that explained 92.8% of the total variance. We performed epigenome-wide association studies (EWAS) for each of the ten PCs correcting for familial structure and other covariates.Results 221 unique CpGs reached genome-wide significance at timepoint 1 (T1) after Bonferroni correction. PC7 accounted for the majority of associations (204), which correlated with loadings of eosinophil counts and immunoglobulin levels. Enrichment analysis via the EWAS Atlas identified 190 of these CpGs to be previously identified in EWASs of asthma and asthma-related traits. Proximity assessment to previously identified SNPs associated with asthma identified 17 unique SNPs within 1 MB of two of the 221 CpGs. EWAS in 182 individuals with epigenetic data at a second timepoint (T2) identified 49 significant CpGs. EWAS Atlas enrichment analysis indicated that 4 of the 49 were previously associated with asthma or asthma-related traits. Comparing the estimates of all the significant associations identified across the two time points (271 in total) yielded a correlation of 0.81.Conclusion We identified 270 unique CpGs that were associated with PC scores generated from 35 clinical markers of asthma, either cross-sectionally or 10 years later. A strong correlation was present between effect sizes at the 2 timepoints. Most associations were identified for PC7, which captured blood eosinophil counts and immunoglobulin levels and many of these CpGs have previous associations in earlier studies of asthma and asthma-related traits. The results point to using this robust DNA methylation profile as a new, stable biomarker for asthma.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from the Amsterdam Public Health Institute (personalized medicine innovation grant); the Avera Institute, Sioux Falls (USA); the National Institutes of Health (NIH R01 HD04215701A1, MH081802, and Grand Opportunity grants: 1RC2 MH089951 and 1RC2 MH089995); the Netherlands Organization for Scientific Research (NWO): Netherlands Twin Registry Repository: researching the interplay between genome and environment (NWO Groot 480 15 001/674); Biobanking and Biomolecular Research Infrastructure (BBMRI NL, NWO 184.033.111); the BBRMI NL financed BIOS Consortium (NWO 184.021.007), Genotype/phenotype database for behavior genetic and genetic epidemiological studies (ZonMw Middelgroot 911 09 032); and large scale infrastructures XOmics (184.034.019). DIB acknowledges the Royal Netherlands Academy of Science Professor Award (PAH/6635). AJVA acknowledges the University of South Dakota Wesley H. Parke Research Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-wide Assurance- FWA00017598; IRB/institute codes, NTR 03-180).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll NTR data can be requested from bona fide researchers (https://ntr-data-request.psy.vu.nl/). Because of the consent given by the study participants, the data cannot be made publicly available. The pipeline for DNA methylation–array analysis developed by the Biobank-based Integrative Omics Study (BIOS) consortium is available at https://molepi.github.io/DNAmArray_workflow/ (https://doi.org/10.5281/zenodo.3355292).